Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Regeneron antibody cocktail wins emergency use authorization

By Brian Buntz | November 24, 2020

Regeneron Pharmaceuticals (NSDQ:REGN) has announced that the FDA has granted emergency use authorization (EUA) for the combination of casirivimab and imdevimab to treat COVID-19. 

The monoclonal antibody cocktail is reportedly the first treatment to show “statistically significant anti-viral activity” against COVID-19, according to its developer. In a trial, the combination of drugs cut hospitalization or emergency room visits for high-risk patients compared to placebo. 

FDA has cleared the way for the monoclonal antibodies to be used for newly diagnosed SARS-COV-2 cases in high-risk patients. 

The drug is not authorized for COVID-19 patients who are hospitalized or on oxygen therapy.

President Trump received the drug when hospitalized with COVID-19 in October. 

The U.S. government will clear the way for some 300,000 patients to receive the drug cocktail at no charge under a U.S. government allocation program.  

To qualify as “high risk” and thus be eligible for the drug, patients need to be either obese, over 65 or have a specified chronic disease (chronic kidney disease, diabetes or immunosuppressive disease). Patients over the age of 55 are also eligible if they have cardiovascular disease, hypertension or a chronic respiratory disease. Adolescents also qualify for the therapy under certain conditions.  

Casirivimab and imdevimab are administered intravenously.

To date, more than 12.3 million people in the U.S. have been diagnosed with COVID-19, according to Johns Hopkins University.

In October, FDA approved Regeneron’s Inmazep, a mixture of three monoclonal antibodies, to treat Ebola. 


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development, Infectious Disease
Tagged With: coronavirus, covid-19, Donald Trump, FDA, Regeneron
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50